NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?
Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.
One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?
This guy, quote-unquote, has a pretty good analysis here.
Comments are closed.